Details of the Drug
General Information of Drug (ID: DMOQ2R8)
Drug Name |
2-amino-5-phenylthiophene-3-carboxamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
2-amino-5-phenylthiophene-3-carboxamide; 4815-35-4; 2-Amino-5-phenyl-thiophene-3-carboxylic acid amide; CHEMBL382565; 2-AMINO-5-PHENYL-3-THIOPHENECARBOXAMIDE; EN300-04586; AC1LDZKQ; ACMC-209kch; 3-thiophenecarboxamide, 2-amino-5-phenyl-; AC1Q5DNT; CBMicro_037044; Cambridge id 5914467; AC1Q4Z6N; Oprea1_326775; Oprea1_445444; SCHEMBL3510525; ZINC87504; CTK4J0691; DTXSID60351580; UHEGYTDIDBFUJD-UHFFFAOYSA-N; MolPort-000-223-057; HMS1757A19; ZX-AL001522; ANW-30639; STK346852; SBB015475; BDBM50186655; AKOS000274130; ACM4815354
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 218.28 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||